After losing a protracted and contentious battle to buy over-the-counter drug specialist Perrigo Co. in November, top executives of local generic drug giant Mylan are moving on to other opportunities, CEO Heather Bresch said Tuesday.

Speaking at a Goldman Sachs health care conference in Boston, Ms. Bresch said she expected that consolidation in the industry will continue and that Mylan “will continue to be very active on the M&A front.”

“Yes, we liked Perrigo,” she said. “But we didn’t need to have them.”

Mylan, which reincorporated in the Netherlands but maintains its operational headquarters in Cecil, remains interested in expanding into over-the-counter medications, she said.

Advertise with us

“Perrigo was one way to get there. ... There’s other ways to get there,” the CEO said. “There’s product acquisition opportunities. There’s other companies.”

During the battle to win the support of Perrigo shareholders, Mylan had pledged to ask shareholders of a combined Mylan-Perrigo to vote on changes to the company’s corporate governance, including eliminating a controversial Dutch poison pill anti-takeover defense that Mylan had used to help block an unsolicited buyout offer from Israel’s Teva Pharmaceutical Industries.

On Tuesday, the conference moderator asked Ms. Bresch if Mylan management still had the “appetite” to make the governance changes, and if so, when?

“We absolutely will continue to have conversations and listen,” the chief executive said.

Last year was “a bruising year for your relationship with shareholders,” the moderator said, noting that the company had rejected Teva’s $82-per-share offer yet Mylan’s stock is now trading in the low $50s.

Advertise with us

“That’s a big gap you’ve got to fill,” the moderator said.

“I think we’ve said we’ll deliver that plus more,” Ms. Bresch responded.

Company executives plan to provide an updated outlook for 2016 and beyond in February. “We feel great about the opportunities that are coming here over the next couple of years,” Ms. Bresch said.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.